The estimated Net Worth of Omead Ostadan is at least $14.9 Milión dollars as of 20 April 2022. Mr Ostadan owns over 52,042 units of Seer stock worth over $618,369 and over the last 9 years he sold SEER stock worth over $13,560,888. In addition, he makes $745,736 as Part Time Pres a COO & Director at Seer.
Mr has made over 52 trades of the Seer stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 52,042 units of SEER stock worth $529,788 on 20 April 2022.
The largest trade he's ever made was selling 52,042 units of Seer stock on 20 April 2022 worth over $529,788. On average, Mr trades about 3,951 units every 37 days since 2015. As of 20 April 2022 he still owns at least 384,080 units of Seer stock.
You can see the complete history of Mr Ostadan stock trades at the bottom of the page.
Omead Ostadan is the Part Time Pres, COO & Director at Seer.
As the Part Time Pres a COO & Director of Seer, the total compensation of Mr Ostadan at Seer is $745,736. There are 2 executives at Seer getting paid more, with Dr. Omid C. Farokhzad Ph.D., M.D. having the highest compensation of $972,082.
Mr Ostadan is 49, he's been the Part Time Pres a COO & Director of Seer since . There are 5 older and no younger executives at Seer. The oldest executive at Seer, Inc. is David R. Horn, 53, who is the Exec. VP & Chief Financial Officer.
Omead's mailing address filed with the SEC is C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY, CA, 94065.
Over the last 7 years, insiders at Seer have traded over $150,878,393 worth of Seer stock and bought 1,798,420 units worth $33,507,980 . The most active insiders traders include Omid Farokhzad, Terrance Mcguire a Growth Fund Limited Partner.... On average, Seer executives and independent directors trade stock every 60 days with the average trade being worth of $227,813. The most recent stock trade was executed by Dipchand Nishar on 14 June 2024, trading 12,109 units of SEER stock currently worth $21,554.
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Seer executives and other stock owners filed with the SEC include: